Colorectal cancer trials in China

In China 614 Also abroad 1933

614 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Hohhot, Jinan, Jining, Jinzhou, Lanzhou, Meizhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an
Age
18 years and over
People
700 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07284849 · EU 2025-523735-19-00
Phase 1/2Taking people
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Where
Beijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
Age
18 years and over
People
220 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00
Phase 2Taking people
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
Where
Wuhan
Age
18 years to 75 years
People
33
Run by
Renmin Hospital of Wuhan University
See details and how to joinNCT07896096
Phase 2Taking people
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Where
Beijing
Age
18 years and over
People
46
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07896681
Phase 2Not yet taking people in China
Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
Where
Guangdong
Age
18 years and over
People
412
Run by
RemeGen Co., Ltd.
See details and how to joinNCT07895355
Phase 2/3Taking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Jiangsu, Nanning, Nanyang, Shanghai, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Yangzhou
Age
18 years and over
People
990 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221357 · EU 2025-523224-45-00
No phaseEnrolling by invitation
Reinforced Versus Conventional Anastomosis in Laparoscopic Low Rectal Cancer Resection: A Comparative Study
Where
Shanghai
Age
18 years to 85 years
People
300
Run by
Shanghai 10th People's Hospital
See details and how to joinNCT07346534
Phase 2Taking people
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
Where
Shanghai
Age
18 years to 75 years
People
50
Run by
Ruijin Hospital
See details and how to joinNCT07888309
Phase 2Taking people
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Where
Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Shanghai, Wuhan
Age
18 years and over
People
140 worldwide
Run by
Vividion Therapeutics, Inc.
See details and how to joinNCT07811193 · EU 2026-525507-26-00
Phase 2Taking people
Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
Where
Shanghai
Age
18 years and over
People
31
Run by
Fudan University
See details and how to joinNCT07884188
Phase 2Taking people
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Where
Shanghai
Age
18 years to 75 years
People
116
Run by
Fudan University
See details and how to joinNCT06841159
Phase 3Taking people
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Where
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanning, Shenyang, Taiyuan, Ürümqi, Wuhan, Wuxi, Yinchuan, Zhengzhou
Age
18 years and over
People
990 worldwide
Run by
AbbVie
See details and how to joinNCT07525206 · EU 2025-521712-19-00
No phaseNot yet taking people in China
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
Where
Shanwei
Age
18 years to 80 years
People
2,000
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07880106
Phase 2Not yet taking people in China
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Where
Guangzhou, Shanghai
Age
18 years and over
People
229
Run by
Sun Yat-sen University
See details and how to joinNCT07621497
Phase 1Taking people
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
Where
Beijing, Guangzhou
Age
18 years to 74 years
People
120
Run by
Shanghai EpimAb Biotherapeutics Co., Ltd.
See details and how to joinNCT07649655
Phase 1/2Taking people
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Where
Chengdu, Guangzhou, Guilin, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Tianjin
Age
18 years to 75 years
People
369
Run by
Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07791758
Phase 3Not yet taking people in China
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Where
Shanghai
Age
18 years to 75 years
People
480
Run by
Fudan University
See details and how to joinNCT07877597
No phaseTaking people
Mesogastrium Metastasis in Colon Cancer
Where
Wuhan
Age
18 years to 75 years
People
50
Run by
Jichao Qin
See details and how to joinNCT04980287
Phase 3Taking people
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Where
Jinan
Age
18 years to 75 years
People
210
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT06850090
Phase 2Taking people
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Where
Guangzhou
Age
18 years to 75 years
People
50
Run by
Sun Yat-sen University
See details and how to joinNCT07448142
No phaseTaking people
Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer
Where
Jinan
Age
18 years and over
People
180
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT07595107
Phase 2Not yet taking people in China
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
Where
Beijing
Age
18 years and over
People
50 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07814417 · EU 2026-526138-23-00
Phase 2Not yet taking people in China
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Where
Hangzhou
Age
18 years and over
People
120
Run by
Bing Xia
See details and how to joinNCT07875465
Phase 1Not yet taking people in China
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
Where
Beijing, Hangzhou
Age
18 years to 75 years
People
66
Run by
Neowise Biotechnology
See details and how to joinNCT07875920
Phase 2Taking people
A Study of YL202 in Patients With Advanced Solid Tumors
Where
Changsha
Age
18 years and over
People
100
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07202364